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Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-
controlled diet. This paper reviews the eﬃcacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-
term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn
therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine
and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No
current pharmacotherapy possesses the eﬃcacy needed to produce substantial weight loss in morbidly obese patients. Meta-
analyses support a signiﬁcant though modest loss in bodyweight with a mean weight diﬀerence of 4.7kg (95% CI 4.1 to 5.3kg)
for rimonabant, 4.2kg (95% CI 3.6 to 4.8kg) for sibutramine and 2.9kg (95% CI 2.5 to 3.2kg) for orlistat compared to placebo
at ≥12 months. Of the Phase III pharmacotherapies, lorcaserin, taranabant, topiramate and bupropion with naltrexone have
demonstrated signiﬁcant weight loss compared to placebo at ≥12 months. Some pharmacotherapies have also demonstrated
clinical beneﬁts. Further studies are required in some populations such as younger and older people whilst the long term safety
continues to be a major consideration and has led to the withdrawal of several drugs.
1.Introduction
Management strategies for weight reduction in obese indi-
viduals include physical interventions such as exercise, diet,
and surgery, behavioural therapies, and pharmacological
treatments. These strategies may be used alone or in combi-
nation for greater eﬃcacy. Most randomized controlled trials
(RCTs) evaluating pharmacotherapies include a calorie-
controlled diet, and some also encourage participants to
increase their physical activity.
Drugs used to induce weight loss may reduce appetite
or increase satiety, reduce the absorption of nutrients, or
increaseenergyexpenditure.Weightlosswithpharmacother-
apies is generally modest, that is, usually 2 to 7.9kg more
than that achieved with placebo treatment [1]. In the past
drug therapies available have included thyroid hormone,
dinitrophenolandamphetamines,followedbyamphetamine
analogues, aminorex, and the fenﬂuramines [1]. More
recently a number of newer agents have been trialed though
only orlistat and sibutramine were approved for long-
term use (≥24 weeks). Following the recent withdrawal of
sibutramine this leaves only orlistat (Table 1).
Amongst the drugs marketed for weight loss there
have been several instances of market withdrawal due to
serious adverse events. The agents involved include dinitro-
phenol, aminorex, the fenﬂuramines, phenylpropanolamine
and most recently rimonabant. Other drugs such as the
amphetamines are severely restricted due to their abuse
potential. Fenﬂuramine and dexfenﬂuramine were recalled
from the world market in 1997 due to concerns of an
increased prevalence of valvular heart disease, and the pos-
sible association with primary pulmonary hypertension [2–
6]. In April 2000, the European Medicines Agency (EMEA)
recommended the withdrawal of several weight loss drugs
from the market including phentermine, amfepramone
(diethylpropion) and mazindol due to an unfavourable risk2 Journal of Obesity
Table 1: Drugs used for weight loss in obesity.
Drug Introduced Mechanism of action Status
Dinitrophenol 1930s Increases metabolic rate Withdrawn—risk of neuropathy and
cataracts
Amphetamines:
dexamphetamine,
methamphetamine
1936 Appetite suppression
Banned, restricted or
discouraged—dependency and abuse
potential, cardiovascular adverse eﬀects
Amphetamine-like
analogues: Phentermine,
diethylpropion,
phenylpropanolamine
1959-US Appetite suppression Diethylpropion—available for short-term
use (≤12 weeks)
Phentermine—available for short-term
use (≤12 weeks) in some countries,
withdrawn 2000 (UK)
Phenylpropanolamine-withdrawn
2000—increased risk haemorrhagic
stroke
Aminorex 1965 Appetite suppression Withdrawn 1968—pulmonary
hypertension
Mazindol 1970s Appetite suppression Discontinued 1993—Australia
Fenﬂuramine 1963-Europe
1973-US Appetite suppression Withdrawn 1997—valvular heart disease,
pulmonary hypertension
Dexfenﬂuramine 1985-Europe
1996-US Appetite suppression Withdrawn 1997—valvular heart disease,
pulmonary hypertension
Orlistat 1998-Europe
and US Decreased fat absorption Also available over-the-counter in several
countries
Sibutramine
1997-US
2001-Europe Appetite suppression
Temporarily withdrawn 2002
Italy-concerns of raised risk of heart
attacks and strokes
Increase in contraindications 2010-US,
Australia
Suspension of market authorization 2010
Rimonabant 2006-Europe Withdrawn 2009—potential of serious
psychiatric disorders
to beneﬁts ratio [7]. This was followed by the voluntary
withdrawalofmedicationscontainingphenylpropanolamine
due to reports of haemorrhagic stroke in women [8]
(Table 1).
Rimonabant was approved as an adjunct to diet and
exercise for the treatment of obese or overweight patients
by the EMEA in 2006. However the FDA never approved
its use in the US due to serious safety concerns. Then in
January 2009, the EMEA withdrew market authorisation for
rimonabant in all countries of the European Union due to
an increased risk of psychiatric adverse events, including
depressed mood disorders, anxiety, and suicidal ideation [9–
11]. Concern was recently raised regarding the safety of
sibutramine, following earlier reports of increased systolic
and diastolic blood pressure and heart rate [10]. With this
concern in mind, the safety was investigated in patients
with a history of cardiovascular disease in the Sibutramine
Cardiovascular Outcomes Trial (SCOUT). The release of
preliminary results from SCOUT led to the compulsory
inclusion of contraindications and precautions in the US
and Australian product information, whilst the EMEA
recommended total suspension of market authorisation for
the drug in Europe [12–16]. Following the subsequent
publication of the SCOUT study [17] the FDA considered
whether to severely restrict access to the sibutramine or
remove it from the market. Sibutramine was subsequently
withdrawn by the manufacturer.
Some drugs which had demonstrated positive weight
loss potential such as taranabant have been abandoned
during late phase clinical trials due to unacceptable adverse
events. Whilst axokine, a ciliary neurotrophic factor that
was administered as a daily subcutaneous injection, was
abandoned due to the low percentage of responders as a
result of the development of antibodies in the majority of
patients taking the drug [18].
Theeﬃcacyandsafetyoflong-termdrugtherapyisavery
important consideration in the management obesity which
often requires ongoing therapy to achieve and maintain the
weight loss. This paper provides a review of the eﬃcacy
and safety of drug therapies for weight loss with at least
six months of patient follow-up focusing on randomised
controlled trials (RCTs) published over the last 4 years of
recent past and current pharmacotherapies, as well as those
in late phase clinical trials.Journal of Obesity 3
2. Measuring Effectiveness of Drug Therapy
There are some challenges in establishing the medium
and longer-term eﬃcacy of pharmacotherapies designed to
induceweightloss.Theseincludethecontinuanceofpatients
throughout the entire study duration and the likelihood that
patients who report more weight loss will be more likely
to complete the study. In an eﬀort to control bias from
this source the use of last observation carried forward is
commonly used to approximate weight loss for the patients
withdrawing from a study [7, 19, 20].
There is also some controversy as to which primary
outcome measures are best to evaluate the eﬃcacy of drug
therapies, that is, absolute weight loss (in excess of placebo),
percentage weight loss, percentage of patients achieving
≥5% or ≥10% weight loss of initial weight, BMI, or waist
circumference (WC). The length of time over which weight
loss is sustained is also important which implies prolonged
follow-up, at least twelve months or if possible longer. In
studies involving children, the BMI appears to be the most
appropriate measure of eﬀectiveness [21]. Secondary eﬃcacy
endpoints are increasingly reported especially in more recent
studies, and these include clinical measures such as blood
pressure, glycaemic control (blood glucose or HbA1C levels)
and cholesterol levels [14, 22, 23].
3. Past Drug Therapies and Current
ApprovedDrugs
Drugs that have been prescribed or evaluated for obesity
may reduce fat absorption or regulate satiety via their
action on serotonin, noradrenergic or dopaminergic or
the cannabinoid receptor systems in the brain (Table 2)
[1, 3, 24–26].
3.1. Amphetamines and Amphetamine-Like Analogues. Am-
phetamines and amphetamine-like analogues (phentermine,
diethylpropion, phenylpropanolamine) are indirect-acting
sympathomimetic agents that act by releasing noradrenaline
(NA) from presynaptic vesicles in the lateral hypothalamus
[1]. Mazindol, a related but discontinued drug, blocks the
reuptake of NA by presynaptic neurons (Table 2)[ 1]. The
increase in NA concentration within the synaptic cleft results
in the stimulation of β2-adrenergic receptors and a resultant
inhibition of appetite.
There is little data from large randomized controlled
trials (RCTs) relating to the long-term eﬃcacy or safety of
amphetamines and amphetamine-like analogues, especially
when used as monotherapy. These drugs have limited use
in the routine management of obesity and are not currently
approved for long-term use. Phentermine has been available
since the late 1950s and is approved for short-term use in
the US and Australia (Table 2). It has been evaluated as both
monotherapy and as combination therapy though not in
large-scale studies [27, 28]. A 36-week RCT in 108 over-
weight women demonstrated a mean weight loss of 12.2kg
(13%) with phentermine (30mg daily) compared to 4.8kg
(5.2%) with placebo (P<. 001). Phentermine has been used
in combination with fenﬂuramine and with ﬂuoxetine [29].
Combination therapy with phentermine (15mg) and fen-
ﬂuramine (60mg), demonstrated signiﬁcantly more weight
loss than placebo in a 28-week RCT (15.5% versus 4.9%,
P<. 001) [28]. Phentermine is currently under evaluation
in combination with topiramate and with pramlintide (see
Drug Monotherapies and Combination Therapies in Clinical
Development).
3.1.1. Diethylpropion (amfepramone). another ampheta-
mine-like analogue has been available for weight loss since
the early 1960s; however there are few if any RCTs of its
long-term use especially with large sample sizes [30, 31].
Diethylpropion (75mg daily) demonstrated signiﬁcantly
greater weight loss in a small 24-week study of 20 patients
than placebo (11.6kg versus 2.5kg, P<. 01) [31]. Recently,
diethylpropion (50mg twice a day) was shown to be more
eﬀective than placebo in a small 6-month RCT with 69 obese
adult patients (9.3kg [95% CI 7–11.5kg] versus 3.1kg [95%
CI 1.8–4.3kg], P<. 0001) [32]. Greater than 5% weight
loss was achieved in 67.6% of diethylpropion patients and
25.0% of those receiving placebo (P = .0005). After further
6 months during an open label period of the study patients
who were originally in the diethylpropion group lost a mean
of 10.1kg (95% CI 7.5–12.8). The most common side eﬀects
were dry mouth and insomnia (P = .02 and P = .009,
respectively). These were experienced in the ﬁrst 3 months
b u tb e c o m el e s sa p p a r e n tw i t hc o n t i n u i n gt r e a t m e n t[ 32].
3.2. Fenﬂuramines. Fenﬂuramine and dexfenﬂuramine ele-
vate serum levels of serotonin (5HT) in the central nervous
systembystimulating5HTreleaseandinhibitingitsreuptake
(Figure 1). Increased levels of 5HT appear to stimulate the
hypothalamus, which controls satiation as well as mood,
sleep, body temperature and other vital functions. These
agents also activate melanocortin 4 receptors that in turn
stimulate activation of 5-HT2C receptors, producing an
increased release of 5HT within the hypothalamic-pituitary-
adrenal axis which is claimed to lead to hypophagia and
anorexia [33–36].
A meta-analysis of RCTs with fenﬂuramine and dexfen-
ﬂuramine demonstrated higher weight loss than placebo
following up to 12 months of treatment. The greatest eﬃcacy
was shown following 3 months treatment, 3.7kg weight loss
[37].
Although RCTs with fenﬂuramines (fenﬂuramine and
dexfenﬂuramine), either alone [38, 39] or with phenter-
mine [40], demonstrated signiﬁcant weight-loss, they were
withdrawn from the market due to increased reports of
valvular heart disease and primary pulmonary hypertension
[2,3,29,41–43]).Theprevalenceratesofbothvalvularheart
disease and primary pulmonary hypertension were higher
following longer exposure to the fenﬂuramines [3].
3.3. Antidepressants
3.3.1. Fluoxetine, Bupropion. Fluoxetine, a selective sero-
tonin reuptake inhibitor (SSRI) that augments 5HT within
the central nervous system has been prescribed oﬀ-label for
weight loss. Although signiﬁcant weight loss was reported4 Journal of Obesity
Table 2: Central mechanisms of action of anti-obesity pharmacotherapies.
Central Subsystem Drugs targets Possible receptor subtypes
involved
Monoamine system(indirect
agonists and subtype selective
receptor antagonists)
Single therapies
(i) Dex/fenﬂuramine (WD), ﬂuoxetine (i) 5HT
(ii) Phentermine/Diethylpropion (ST) (ii) DA, NA
(iii) Sibutramine (iii) α1, β1, β3adrenergic and
5HT2B/C
(iv) Bupropion (iv) DA, NA
(v) Tesofensine (v) DA, NA, 5HT
(vi) Lorcaserin (vi) 5HT2C
Opioid system(μ-opioid receptor
antagonist)
(i) Naltrexone (i) μ-opioid
(ii) Topiramate (ii) AMPA/kainite glutamate∗
(iii) Zonisamide (iii) 5HT, DA∗
Cannabinoid system
Single therapies:
(i) Rimonabant (WD) (i) CB1
(ii) Taranabant (DC) (ii) CB1
Monoamine/Opioid system Bupropion/naltrexone (i) DA, NA/μ-opioid
Bupropion/zonisamide (ii) DA, NA/5HT, DA∗
NeuropeptideY/Agouti-related
peptide system Pramlintide/metreleptin (i) Calcitonin receptor∗/Leptin
receptor
5HT: serotonergic, DA: dopaminergic, NA: noradrenergic, WD:withdrawn; DC: phase III trials discontinued; ST: short term;∗: unknown; AMPA: α-amino-
3-hydroxyl-5-methyl-4-isoxazole-propionate.
with 60mg of this agent in short-term studies of 6–8 weeks,
with maximum weight loss achieved at 12–20-weeks, this
i sf o l l o w e db yar e g a i ni nb o d y w e i g h t[ 44–47]. Most RCTs
have not shown a signiﬁcant diﬀerence when ﬂuoxetine was
compared to placebo at 52 weeks [46, 48]. Signiﬁcantly
greater weight loss has however been demonstrated at 8
months when ﬂuoxetine was used in combination with
dexfenﬂuramine (13.4 versus 6.2kg with placebo) [49]. In
clinical practice ﬂuoxetine 10–20mg has been used with
phentermine (i.e., phen-pro or phen-ﬂu) but there are no
RCTs of either the long-term eﬃcacy or safety of this
combination[50].Aretrospectivechartreviewsuggestedthis
combination is not as eﬀective as fenﬂuramine with phenter-
mine [51]. Fluoxetine generally has a tolerable safety proﬁle
with reported adverse events of headache, asthenia, nausea,
diarrhoea, somnolence, insomnia, nervousness, sweating,
and tremor [47].
3.3.2. Bupropion. is another antidepressant which inhibits
reuptake of dopamine (DA) and noradrenaline (NA) result-
ing in a loss of appetite and decreased food intake [52]a n d
modest weight loss in obese people [53–56]. The eﬃcacy
of bupropion as a sustained release (SR) formulation was
demonstrated at 48 weeks in obese patients [53]. Weight
loss was dose dependent with 7.5% initial weight loss
for subjects taking 300mg bupropion-SR and 8.6% with
400mg [53]. Bupropion-SR was generally well tolerated, and
weight loss was maintained at 48 weeks. A meta-analysis of
weight loss treatments which included 5 bupropion studies
reported a mean weight loss of 2.8kg (95% CI, 1.1 to
4.5kg) at 6 to 12 months with bupropion compared to
placebo [56]( Table 3). Although bupropion is not approved
for weight loss, it has been used oﬀ-label and is currently
under evaluation as combination therapy with naltrexone,
a μ-opioid receptor antagonist and zonisamide, a GABA
receptor activator (s e eD r u gM o n o t h e r a p i e sa n dC o m b i n a t i o n
Therapies under Investigation).
3.4. Orlistat. Orlistat (a gastrointestinal lipase inhibitor) is
a synthetic drug derived from a naturally occurring lipase
inhibitor. It does not directly act on appetite as other
obesity pharmacotherapies, rather it decreases fat absorption
by binding to pancreatic lipase, the principle enzyme that
hydrolyses triglyceride (Table 2)( Figure 1)[ 26]. A detailed
review of the eﬃcacy of orlistat treatment in obesity has
previously been described [1]. The long-term eﬃcacy of
orlistat (120mg three times daily) for weight loss has been
demonstrated in several RCTs of 2- to 4- year therapy
compared to placebo [61–64], as well as improvements in
blood pressure, insulin resistance, and serum lipid levels [57,
64–66]. Several systematic reviews in adults [56, 57, 67–70]
and a systematic review with 2 short-term studies in
adolescents [71] demonstrated signiﬁcantly more weight loss
with orlistat than placebo, 6.2kg (95% CI, 1.7 to 14.0kg).
The most commonly experienced side eﬀects of orlistat
are gastrointestinal and include diarrhoea, ﬂatulence, bloat-
ing, abdominal pain, and dyspepsia [25, 66, 70]. Recently,
severe liver injury has been reported. The FDA received
32 reports of serious liver injury in patients using orlistat
between 1999 and October 2008, including 6 cases of liver
failure [72]. This prompted the FDA to undertake a review
of the safety of orlistat treatment. The review identiﬁed aJournal of Obesity 5
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Figure 1: Overview of central and peripheral functions associated with anti-obesity pharmacotherapies.
total of 13 cases of severe liver injury (12 foreign reports with
orlistat 120mg and a US report with the lower dose over-the-
counter product [orlistat 60mg]) and in May 2010 led to a
label revision and the addition of a warning of severe liver
injury.
3.5. Sibutramine. Sibutramine, a 5HT and NA uptake
inhibitor, was originally developed as an antidepressant and
subsequently found to reduce appetite [26]. It has 2 active
metabolites, which inhibit NA and 5HT uptake (and to a
lesser extent DA) without any direct eﬀect on neuronal NA,
DA and 5HT release. It has been suggested that sibutramine
has a dual action to facilitate weight loss, an anorectic
eﬀect suggested to be mediated through the central α1and
β1 adrenergic receptors and thermogenic eﬀects through β3
adrenergic receptors peripherally [73].
Maximal weight loss occurs by 6 months with sibu-
tramine treatment [74, 75] and was dose related [74, 76, 77].
Sibutramine has consistently demonstrated signiﬁcantly
more weight loss than placebo in several RCTs with ≥1
year of therapy [1, 74, 75, 78–80]. Systematic reviews which
included 7 sibutramine RCTs reported 4.3kg (95% CI:
3.6kg to 4.9kg) or 4.6% (95% CI: 3.8% to 5.4%) greater
weight loss than placebo [58, 70]( Table 3). There was
≥10% weight loss in 18% (95% CI: 11% to 25%) more
sibutramine patients than placebo [58, 70]. Attrition rates
in sibutramine studies were approximately 30%–40% [58].
In RCTs of 3 to 12 months that compared sibutramine and
orlistat, the weighted mean diﬀerence in weight loss was
2.2kg (95% CI 0.5–3.9) in favour of sibutramine [59]. A
systematicreviewinadolescentswhichincluded5short-term
studies has demonstrated signiﬁcantly more weight loss with
sibutraminethanplacebo,5.3kg(95%CI,3.5to7.2kg)[71].
Although treatment with sibutramine has resulted in
lowered concentrations of cholesterol and triglycerides,
blood pressure and pulse rate may be increased [57].
Increases in diastolic blood pressure (DBP) with sibutramine
were reported in 2 meta-analyses, one in hypertensive
patients which included 2 studies where the weighted mean
diﬀerence was +3.2mmHg (95%CI +1.4 to +4.9mmHg)6 Journal of Obesity
Table 3: Comparative eﬃcacy of pharmacotherapy from recent meta-analyses of long-term studies in adults (12 months or more).
Drug No. of studies Total subjects Mean weight diﬀerence
(kg) (95% CI)
Reference
Rimonabant 4 Placebo: ∼1600
Rimonabant: ∼2500 4.7 (4.1, 5.3) [9, 57, 58]
Orlistat 14 Placebo: 4509
Orlistat: 4948 2.9 (2.5, 3.2) [57, 58]
Sibutramine 7 Placebo: 699 Sibutramine:
837 4.2 (3.6, 4.8) [57, 58]
Sibutramine
Orlistat 5 Sibutramine: 229 Orlistat:
249 3.4 (2.3, 4.6) [59]
Bupropion
∗ 5 Bupropion: 618
Placebo: 344 2.8kg (1.1 to 4.5kg) [56]
CI: conﬁdence interval; ∗ 6t o1 2m o n t hs t u d i e s .
Note: another meta-analysis of 5 studies with rimonabant compared to placebo, did not provide mean weight diﬀerence in kg, however the odds ratio was
1.07 (95% CI 0.9, 1.3) [60].
[66], whilst another reported a placebo-controlled change in
DBP of +1.7 (95% CI 0.7, 2.6) and a small nonsigniﬁcant
change in systolic BP (+0.5mmHg, 95% CI −1.1, 2.1) [81].
Although sibutramine may reduce body weight by a similar
amount as orlistat in hypertensive patients, it does not have
the same beneﬁcial eﬀects on BP [65].
Weight loss was signiﬁcantly greater at 1 year when sibu-
tramine was combined with lifestyle modiﬁcation (10.8% ±
10.2%, mean±SD, P<. 05) and diet (16.5% ± 8.0%, P<
.05) than when sibutramine was used alone (4.1% ± 6.3%)
[82]. Although the addition of orlistat to sibutramine ther-
apy does not appear to enhance weight loss [83, 84], combi-
nation therapy with the amylin analogue pramlintide is pro-
ducingpromisingresults[85](seeTitledDrugMonotherapies
and Combination Therapies under Investigation).
Apart from increases in BP and heart rate the most
common side-eﬀects reported with sibutramine are dry
mouth, constipation, and headache [57, 66].
Following the report of two sibutramine-related deaths
in Britain and serious side eﬀects in France, the EMEA
demanded a long-term trial in patients at high risk of
cardiovasculardisease hencethe Sibutramine Cardiovascular
Outcome trial (SCOUT) was initiated [86, 87]. SCOUT is
a double-blind, randomized, placebo-controlled outcome
trial in 10,742 overweight or obese patients at high-risk
for cardiovascular disease that commenced recruitment in
December2002.Ofthetotalpatients97%hadcardiovascular
disease, 88% had hypertension, and 84% had type 2 diabetes
[88]. Until recently the only published results from SCOUT
were from the 4–6-week lead in period [13–15, 87, 89]. At
6 weeks there was a signiﬁcant reduction in body weight
(2.2kg), waist circumference (2.0cm), systolic (3.0mmHg)
and diastolic blood pressure (1.0mmHg) with sibutramine
treatment, however pulse rate was increased by 1.5bpm
(all P<. 001) [89]. Results were similar for the diabetic
patients in the study, that is, a 2.1kg decrease in weight
and decrease in blood pressure by 3.5/1.0mmHg with
sibutramine compared to placebo [14]. A total of 9,800
patients were followed up for six years. The preliminary
data released in late 2009, suggested that sibutramine was
associated with a higher rate of CV events than placebo
[90], whilst data from a FDA early communication indicated
that there was an increased rate of CV events (heart attacks,
strokes, resuscitated cardiac arrest, CV death) in patients
with cardiovascular disease and diabetes (11.9% placebo,
13.9% sibutramine, hazard ratio 1.18, 95% CI 1.02–1.35,
P = .023) [91]. The EMEA concluded that the beneﬁts of
sibutramine did not outweigh the risks and recommended
that all marketing authorisations for medicines containing
sibutramine should be suspended throughout Europe [10].
The FDA initially allowed sibutramine to be available, but
asked for stronger warnings on the product labels [92]. The
warning recommended that sibutramine should not be used
by people who have a history of stroke or heart attacks and
uncontrolled high blood pressure. The recent publication of
the SCOUT study which had a mean follow-up period of 3.4
years reported a large number of patients that discontinued
treatment (40.2% sibutramine, 42.3% placebo), a higher risk
of cardiovascular outcome with sibutramine (11.4% versus
10%, hazard ratio 1.16 95% CI 1.03–1.31, P = .02). [17]I n
particulartherewasahigherrateofnonfatalMIandnonfatal
stroke for sibutramine (4.1% and 2.6%, resp.) than placebo
(3.2% and 1.9%).
A 3-year prospective observational study of 15,686
patients prescribed sibutramine in New Zealand has not
demonstrated a higher risk of death from a cardiovascular
event [93]. The FDA is currently reviewing the potential
beneﬁts and risks of sibutramine [94].
3.6. Rimonabant. Rimonabant, an endocannabinoid recep-
tor (subtype 1) blocker, was developed as a result of
observations on the appetite stimulation associated with
recreational cannabis use (Table 2). The drug has a range of
both central and metabolic peripheral eﬀects and had also
been investigated for smoking cessation [26, 95].
Attritionratesinapooledstudyof5,580patientswithout
diabetes and 1,047 patients with diabetes taking rimonabant
20mg daily for one year and a hypocaloric diet were approx-
imately 40% [96]. In the nondiabetic patient subgroup,
rimonabant reduced body weight by 6.5kg compared toJournal of Obesity 7
placebo (P<. 001). Weight-loss of ≥5% was achieved in
50.8% of the treatment group, and waist circumference was
reduced by 6.4cm compared to placebo (P<. 001) (Table 4)
[96]. There was an improvement in glycaemic control in
diabetic patients with a reduction in mean HbA1C levels of
0.6% (P<. 001) [96]. Discontinuation due to side-eﬀects
occurred in 13.8% of rimonabant patients and in 7.2% of
placebo patients. The most commonly experienced adverse
events were gastrointestinal disorders, mood alterations with
depressive symptoms, anxiety, dizziness, nausea, and upper
respiratory tract infections.
FourlargeRimonabantinObesityandRelatedMetabolic
Disorders (RIO) Phase III studies (RIO-Europe, RIO-North
America, RIO-Diabetes, RIO-Lipids) were included in two
meta-analyses and a systematic review to investigate the
eﬃcacy and safety of rimonabant in improving cardiovas-
cular and metabolic risk factors in overweight patients [9,
60]( Table 3). Compared with placebo, rimonabant (20mg)
produced a 4.9kg (95% CI 4.3, 5.0) greater reduction in
body weight as well as improvements in waist circumference
(−3.84cm, 95% CI −4.26, −3.42), high-density lipoprotein
cholesterol, triglyceride levels, and systolic and diastolic BP
[60]. A subsequent meta-analysis which included the 4 RIO
studies provided evidence of the likelihood of experiencing
serious side eﬀects with rimonabant [9]. The odds ratio
(OR) for depression was 2.51 (95% CI, 1.23–5.12) and 3.03
(95%, 1.09–8.42) for anxiety [9]. A systematic review and
meta-analysis reported that the 20mg rimonabant dose was
associated with an increased risk of adverse events (RR 1.35;
95% CI 1.17–1.56), increased discontinuation rate (RR 1.79;
95% CI 1.35–2.38), and psychiatric (RR 2.35; 95% CI 1.66–
3.34), and nervous system adverse events (RR 2.35; 95% CI
1.49–3.70) [100]. The number needed to harm (NNH) for
psychiatricadverseeventswas30[100].Inacomparisonwith
other pharmacotherapies the risk ratios for discontinuation
in RCTs due to adverse events were signiﬁcantly elevated
for rimonabant (2.00; 95% CI 1.66–2.41) and orlistat (1.59;
95% CI 1.21–2.08), but not sibutramine (0.98, 95% CI 0.68–
1.41) [20]. The risk diﬀerence was largest for rimonabant
(7%, 95% CI: 5%–9%; NNH 14, 95% CI: 11–19) compared
with placebo, followed by orlistat (3%, 1%–4%; NNH 39,
95% CI: 25–83), while no signiﬁcant diﬀerence was seen for
sibutramine (0.2%, 95% CI: −3% to 4%; NNH 500).
In late 2008, the manufacturers of rimonabant an-
nounced that all clinical research studies would be stopped
permanently. This announcement followed a decision by
the EMEA to withdraw marketing of the drug as the risks
especially of psychiatric side eﬀects were considered to
outweigh the drug’s beneﬁts [101].
3.7. Systematic Reviews Comparing Several Drug Therapies.
Several meta-analyses and systematic reviews have demon-
strated that pharmacotherapy in combination with a low
calorie diet and in some cases exercise generally results in
a maximum weight reduction at six months of 1–9.6kg,
maintenance of weight loss with continued therapy, and
a regain in weight after drug therapy is discontinued [7,
30]. The largest mean eﬀect sizes were demonstrated with
amphetamines, fenﬂuramines and sibutramine, though no
drug demonstrated clear superiority [30, 58]a n dm o s to f
the drugs have been prescribed for a limited duration. A
systematic review which included 14 RCTs with orlistat,
7 RCTs of sibutramine and 4 RCTs with rimonabant
comparedtoplacebo,reported2.9kggreaterweightlosswith
orlistat than placebo, 4.2kg for sibutramine and 4.7kg for
rimonabant (Table 3). Patients on active drug therapy were
signiﬁcantly more likely to achieve ≥5% and ≥10% weight
loss [57]. Continuation on treatment was a problem with
attrition rates averaging 30%–40% within 12 months [57].
In adolescents a meta-analyses of RCTs with orlistat
and sibutramine demonstrated a mean decrease in weight
between the intervention and control groups of 5.25kg (95%
CI: 3.03–7.48) after a minimum follow-up of 6 months [71].
Systemic reviews of pharmacotherapy for overweight and
obese children, adolescents, and older adults only include a
limited number of mainly short-term studies [21, 102–104]
hence, there is a lack of high-quality evidence to support the
eﬃcacy and safety of drug therapy in these populations.
4. DrugMonotherapies andCombination
Therapies under Investigation
Some already marketed drugs (that are approved for other
indications) and several new agents are currently being eval-
uated for the management of obesity [25, 105, 106]. These
include tesofensine, a pharmacological agent that targets the
inhibition of NA, DA, and 5HT reuptake and, liraglutide a
glucagon-like peptide-1 analog and lorcaserin the selective
serotonin 2C (5-HT2C) receptor agonist (Table 2). There
are also several combination drug therapies in Phase III
trials including bupropion and naltrexone, bupropion and
zonisamide, phentermine and topiramate, and pramlintide
and metreleptin. Some drugs that were in late phase trials
such as axokine, a naturally occurring re-engineered human
protein known as cilary neurotrophic factor, taranabant a
CB1R inverse agonist, and ecopipam a selective dopamine
D1/D5 antagonist have been abandoned, the latter two due
to an increase in psychiatric adverse events. There are also
some weight loss medications that have previously been used
in the management of diabetes that are being evaluated for
weight loss, that is, pramlintide, liraglutide, and exenatide.
4.1. Pramlintide. Pramlintide, a synthetic analog of the
pancreatic hormone amylin, was originally used for the
treatment of type 1 and 2 diabetes. It has been associated
with reduced, appetite, food intake and enhanced satiety
through delayed gastrointestinal motility and is currently
under investigation as a potential treatment for obesity [25,
105]. In a 16-week dose escalation RCT 3.7% mean weight
loss was demonstrated with pramlintide 240μgg i v e na sa
subcutaneous (SC) injection compared to placebo (P<
.001) and ≥5% weight loss was achieved in 31% of patients
(P<. 001) [107]. In obese patients participating in a 4-
month RCT of pramlintide at doses of 120, 240, and 360μg
administered two or three times a day, followed by a single
blind extension to 1 year, weight loss was regained in the
placebo group but maintained or continued in all but the8 Journal of Obesity
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pramlintide 120μg twice daily arm [108]. Nausea was the
most common adverse event.
4.2. Glucagon-Like Peptide-1 (GLP1) Analogues: Liraglu-
tide, Exenatide. Liraglutide and exenatide are glucagon-like
peptide-1 (GLP1) analogues developed and approved for
the treatment of type 2 diabetes (Table 2)[ 109]. Phase III
trials of liraglutide have demonstrated beneﬁcial weight loss
in obese patients. These analogues have a dual mechanism
of action, that is, on the gastrointestinal (GI) tract and
the brain. Signals from the GI tract are sent to the brain
to increase the secretion of leptin, resulting in suppressed
appetite, energy intake and a delay in gastric emptying. A key
beneﬁt with long-term use of liraglutide and exenatide is a
decrease in HbA1c levels and systolic BP [110, 111]. A recent
20weekdose-rangingRCTofliraglutide(1.2,1.8mg,2.4mg,
3.0mg) in comparison with orlistat (120mg) treatment in
564 nondiabetic obese patients demonstrated a mean weight
loss of 4-8kg, 5.5kg, 6.3kg, and 7.2kg, resp. compared with
2·8kg with placebo and 4·1 k gw i t ho r l i s t a t( P = .003
for 1.2mg, P<. 0001 for 1.8–3.0mg liraglutide) [112].
Higher doses of liraglutide (2.4 and 3.0mg) demonstrated
signiﬁcantly greater mean weight loss than orlistat. The most
common adverse events with liraglutide were nausea and
vomiting, but these were not signiﬁcantly diﬀerent to the
placebo group. Patients treated with liraglutide also showed
a signiﬁcant reduction in blood pressure and the prevalence
of prediabetes (84%–96%).
Exenatide is currently only in Phase II trials [113]f o r
obesity but early results from an open-label study have
demonstrated weight loss as well as an improvement in
glycemic control [114].
4.3. Taranabant. Taranabant a cannabinoid CB-1 receptor
(CB1R) inverse agonist which reduces appetite and increases
energy expenditure has been evaluated for the treatment
of obesity [115]. It demonstrated greater weight loss with
higher doses in a 12 week RCT that assessed its safety
and eﬃcacy. Four Phase III trials have been published, two
assessed the risk/beneﬁt proﬁle of low and high doses and
one included patients with type 2 diabetes [23, 116–118].
Mean weight loss after 1 year of taranabant was 5.0kg
with the 0.5mg dose, 5.2kg with the 1mg, 6.4kg with the
2mg compared to 1.4kg for placebo (all P<. 001) [118]
Signiﬁcantly more patients achieved ≥5% and ≥10% loss of
baseline body weight with taranabant than placebo (P<. 001
for all doses) (Table 5). Approximately 80% of patients from
eachtaranabantdosegroupexperiencedoneormoreadverse
events [118].
A study using higher doses (2mg, 4mg, and 6mg)
achieved greater mean weight loss at 1 year of treatment
which persisted to 2 years (Table 5)[ 23]. Although weight
loss with the highest dose of 6mg proved to be the most
eﬃcacious after 1 year of treatment, the adverse events were
signiﬁcantlyincreasedwithincreasingdosesparticularlyseri-
ous psychiatric events which included depression, depressive
mood, anxiety, anger, and aggression [23]. The odds ratios
forsuicidalitywithincreasingdosesoftaranabantafter1year
treatment were 1.74 (95% CI 0.87–3.51) with the 2mg dose,
2.16 (95% CI 1.10–4.25) for 4mg, and 2.34 (95% CI 1.11–
4.96) with the 6mg. Hence, only the lower doses (2mg and
4mg) were used for the remainder of the study.
The overall safety and eﬃcacy proﬁle of taranabant from
the Phase III trials did not support its further development
inthetreatmentofobesity,andclinicaltrialswereceased[23,
117, 119].
4.4. Lorcaserin. Lorcaserin is a selective serotonin 2C recep-
tor agonist (5-HT2C), sharing characteristics similar to fen-
ﬂuramines, which acts through another serotonin receptor
(5-HT2B) that has been associated with cardiac valvular
disease [124]( Table 2).
Recent clinical trials with lorcaserin have demonstrated
eﬀective weight loss compared to placebo along with a good
safety proﬁle [125, 126]. Results from two recently presented
pivotal Phase III trials, BLOOM (Behavioral modiﬁcation
and Lorcaserin for Overweight and Obesity Management)
and BLOSSOM (Behavioral modiﬁcation and Lorcaserin
Second Study for Obesity Management) indicated greater
weight loss with lorcaserin than with placebo (Table 5)[ 120,
127,128].IntheseRCTs,6380non-diabeticpatientsaged18–
66 years with a BMI 27–45kg/m2 were treated for 52 weeks
with lorcaserin 10mg twice daily or with placebo. Using the
pooled data from these two trials, weight loss at 52 weeks
decreased by 5.8% in the lorcaserin group and 2.5% in the
placebo group (P<. 0001) [127]. Weight loss was similar
amongst males and females but was higher in Caucasian
patients than African American patients or Hispanic patients
and patients >50 years lost more weight than younger
patients. Average weight loss at 1 year in the BLOOM study
was 5.8±0.2kg with lorcaserin and 2.2±0.1kgwithplacebo
ones (P<. 001) with 47.5% and 20.3% loosing ≥5% of their
body weight (Table 5)[ 120]. Weight loss was maintained in
67.9% of lorcaserin patients in year 2 and 50.3% of placebo
(P<. 001) (Table 6)[ 120]. After 52 weeks of lorcaserin
treatment, changes in lipid and glucose values were more
favourable in responders than nonresponders, and twice as
many patients responded to lorcaserin as placebo (i.e., ≥5%
body weight loss in 47.1% lorcaserin patients and 22.6%
placebo) [128]. The most frequent adverse events reported
were headache, dizziness and nausea, but these were not
signiﬁcantly diﬀerent between treatment groups (Table 5).
Therewasnoincreaseintherateofcardiacvalvulopathyafter
2-year treatment with lorcaserin [120].
Although the recently published study indicated lor-
caserin was safe and moderately eﬀective, there was a
high dropout rate [120]. Lorcaserin was submitted for
FDA approval however in September 2010 the advisors
recommended against approval as they did not consider that
the potential beneﬁts of the drug outweighed the risks. In
particular they claimed that patients on lorcaserin did not
achieve the percentage point criterion set by the FDA. The
FDA which usually takes the advice of its committees is
expected to decide in October whether to approve lorcaserin.
4.5. Tesofensine. Tesofensine is another novel pharmacolog-
ical agent which inhibits the uptake of presynaptic NA,
DA, and 5HT (Table 2, Figure 1). Tesofensine was discovered10 Journal of Obesity
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Table 6: Recent randomised controlled trials of weight loss therapies with 2-years followup.
Drug No subjects Outcomes Serious
adverse events Reference
Absolute weight loss
(kg) (95% CI)
≥5% weight loss ≥10% weight loss Change in WC
(cm)
Lorcaserin P-684 3.0% ± 0.2% 50.3% 7.7% 4.3 ± 0.2N S [ 120]
L-564 7.0% ± 0.2% 67.9% 22.6% 8.1 ± 0.2
P<. 001 P<. 001 P<. 001 P<. 001
Taranabant P-244 1.4 (0.3, 2.5) 30.3% 13.4 −2.7 (1.5, 3.8) NS [23]
TB 2mg-264 6.4 (5.3, 7.4),
P<. 001 59.6, P<. 001 33, P<. 001
−6.3 (5.2, 7.4)
P<. 05
TB 4mg-260 7.6 (6.5, 8.7),
P<. 001 64.8, P<. 001 37.9, P<. 001
−7.0 (5.9, 8.1),
P<. 01
Absolute weight loss = weight loss from baseline; WC: waist circumference, NR: not recorded, TB: taranabant, NS: not signiﬁcant; P: placebo; L: lorcaserin.
to decrease weight in patients receiving the drug for the
treatment of Alzheimer’s and Parkinson’s disease [129].
Investigators performed a dose-dependent analysis in obese
patients for 14 weeks, demonstrating a mean change in
weightlossfortesofensinedosesof0.125mg,0.25mg,0.5mg
and 1mg of 2.1%, 8.2%, 14.1%, and 20.9%, resp. [129].
Of the total obese patients in the study, 32.1% achieved a
≥5% weight loss with tesofensine, (P<. 001 for 0.25, 0.5,
and 1.0mg versus placebo). No eﬀect on blood pressure
was observed, but there were increases in heart rate with
increasing dose.
Further evidence was demonstrated in another 24-week
Phase IIb randomised dose-dependent tesofensine trial in
203 obese individuals, with 79% of participants completing
the study [99]. Weight loss was dose dependant with 4.5%
weight loss (0.25mg), 9.2% (0.5mg), and 10.6% (1.0mg)
and was greater than that achieved with diet and placebo
(P<. 0001) (Table 4) .T h ed r u gw a sw e l lt o l e r a t e dw i t hn o
signiﬁcant increases in systolic or diastolic blood pressure
however, heart rate was increased by 7.4 beats/min in the
middose group (P = .0001).
4.6. Naltrexone. Naltrexone, ah i g ha ﬃnity and long-acting
opioidreceptorantagonistwhichwasoriginallyproducedfor
the treatment of opioid and alcohol dependence, decreased
food intake and led to weight loss in former narcotic addicts.
The role of opioid receptors in eating behaviour was initially
demonstrated following the administration of naloxone to
rats resulting in a signiﬁcant reduction in short-term food
intake by blocking β-endorphin (Table 2)[ 130]. In RCTs
naltrexone (an analogue of naloxone) has not consistently
demonstratedstatisticallysigniﬁcantweightlossinobeseand
lean subjects [131–134].
4.7. Bupropion Plus Naltrexone (Contrave). Bupropion was
combined with the naltrexone following the recogni-
tion that naltrexone blocks β-endorphin mediated pro-
opiomelanocortin (POMC) autoinhibition to sustain α-
MSH release, whilst bupropion (through DA receptors)
activates POMC neurons and enhances the release of the
anorexiant neuropeptide α-MSH in the hypothalamus [22,
135, 136]. The bupropion-naltrexone combination is said to
tackle the motivation/reinforcement that food brings (DA
eﬀect) and the pleasure/palatability of eating (opioid eﬀect)
[137].
A 24 week dose ranging study of naltrexone/bupropion-
SRdidnotdemonstrateincreasedweightlosswithincreasing
doses of naltrexone (weight loss for 16mg dose was 4.62%
[95% CI: −6.24 to −2.99, P<. 001], for 32mg dose 4.65%
[95% CI: −6.20 to −3.09, P<. 001], and for the 48mg
dose 3.53% [95% CI: −5.15 to −1.90, P<. 001]) (Table 4)
[22]. Nevertheless, weight-loss was maintained in a 24-week
extended period.
An open-label 24-week study demonstrated that naltrex-
one 32mg SR/bupropion-SR 360mg resulted in signiﬁcant
improvements in depressive symptoms in addition to weight
loss and improved control of eating in overweight and obese
women with major depression [138]. Depression scores as
measured with the Montgomery-Asberg Depression Rating
Scale decreased from an average of 23.7 at baseline to 10.5
(consistent with mild depression) at week 12 (P<. 001) and
8.4 (consistent with remission) at week 24 (P<. 001).
Several Phase III trials have been conducted in both
diabeticandnon-diabeticpatientsincludingCOR-I,COR-II,
COR-BMOD and COR-Diabetes [105, 121, 139–141]. COR-
Diabetes was a 56-week RCT of 505 overweight or obese
patients with type 2 diabetes (Hb A1C levels 7% to 10%,
mean 8.0%) randomized to naltrexone 32mg SR/bupropion
360mg SR or placebo [140]. The naltrexone/bupropion
patients lost signiﬁcantly more weight (5.0% versus 1.8%,
P<. 001) at 56 weeks [140] with 44.5% of patients achieving
≥5% loss of body weight compared to 18.9% on placebo.
Greaterimprovementinglycemiccontrolwasachievedinthe
treatment group with average baseline HbA1C reduced by
0.6% compared to 0.1% for placebo. The investigators noted
that over 44% of treated patients achieved the American
Diabetes Association treatment target of <7% for HbA1C
compared to 26% of placebo patients (P<. 001).
This drug combination has generally been welltolerated
in most patients (Table 5). Nausea was the most frequent
adverse event, and this occurred more frequently with higher
naltrexonedoses.Anewdrugapplicationhasbeensubmitted12 Journal of Obesity
for review by the FDA with the outcome expected in
December 2010.
4.8. Bupropion Plus Zonisamide. The combination of bupro-
pion with the epilepsy agent, zonisamide has been evaluated
in three Phase II trials [97, 142–144]. The mechanism
of action for zonisamide has not been fully characterised,
however it has demonstrated biphasic DA and 5HT activity
[142, 145]. The potential of zonisamide in the management
of obesity was demonstrated in a small RCT where zon-
isamide patients experienced signiﬁcantly more weight lost
than those on placebo [145]. A 24-week RCT of bupropion
300mg combined with zonisamide 400mg achieved greater
weight loss (9.2%) than either drugs alone (bupropion 6.6%,
zonisamide 3.6%) or placebo (0.4%) [143]. Similar results
were observed in a randomised open-label study [142].
Weight loss in a 24 week multicentre RCT with either
drug alone and diﬀerent combinations of zonisamide SR
with bupropion SR were 1.4% with placebo, 3.2% with
zonisamide SR 120mg, 5.3% with zonisamide SR 360mg,
2.3% with bupropion SR 360mg, 6.1% with zonisamide SR
120mg/bupropion SR 360mg, and 7.5% for zonisamide SR
360mg/bupropion SR 360mg with ≥5% weight loss in 15%,
27%, 44%, 21%, 47%, 60%, respectively, [97]. The most
frequent adverse events reported were headache, nausea and
insomnia.
Weight loss with zonisamide and bupropion appears to
be greater than that observed with the bupropion/naltrexone
combination over the same period of treatment [22].
4.9. Topiramate Plus Phentermine (Qnexa). Topiramate is a
GABA agonist and an approved antiepileptic drug which
has been trialed as monotherapy for weight loss [1]. It
acts as an appetite suppressant that has been suggested
to inﬂuence kainate/α-amino-3-hydroxy-5-methylisoxozole-
4-propionicacid glutamate receptors, voltage-gated sodium
channels,andγ-aminobutyricacid-Aactivity[146],however
the exact mechanism of action for weight loss is not known
(Table 2). Several RCTs demonstrated greater weight loss
with topiramate monotherapy than placebo with continued
weight loss throughout the duration of the study [1].
However concerns regarding central and peripheral nervous
system adverse eﬀects led to Phase III trials of topiramate
being halted and topiramate being reformulated. As the
sustained release formulation did not have better tolerability
trials were discontinued in December 2004.
The combination of controlled release low dose topira-
mate with low dose phentermine has recently been shown
to be eﬀective for weight loss treatment [147]. A 28-
week RCT using phentermine with topiramate (92mg/15mg
and 46mg/7.5mg doses) demonstrated a 9.2% weight loss
compared to a 6.4% weight loss with topiramate alone,
6.1% for phentermine alone and 1.7% for placebo [123].
The tolerance and safety of this drug combination are
being evaluated in several Phase III trials (EQUATE, EQUIP,
CONQUER). In July 2010 an FDA advisory committee
agreed that the phentermine/topiramate combination was
eﬀective in reducing weight loss however it refused to
endorse a recommendation for the treatment of obesity
due to safety concerns which included increased heart rate,
possible birth defects, and psychiatric problems (depression,
suicidal thoughts, impaired memory and concentration)
[148]. The ﬁnal FDA determination on the drug combina-
tion is expected in late October 2010.
4.10. Pramlintide Combination Therapies. Pramlintide has
been combined with recombinant methyl human leptin
(metreleptin), an adipocyte-derived hormone involved in
long-term signalling of adiposity and energy intake [149].
In early trials this combination of an amylin and a leptin
agonisthasdemonstratedgreaterweightlossthaneitherdrug
alone [148, 149]. Weight loss with pramlintide/metreleptin
was 12.7% ± 0.9% (mean ± SE) to week 20 compared
with 8.4% ± 0.9% for pramlintide (P<. 001) and 8.2% ±
1.3% for metreleptin (P<. 01) [149]. Pramlintide is
also being evaluated in combination with sibutramine and
phentermine [85]. In a 24-week open-label study weight
loss was in subjects taking pramlintide and sibutramine
was 11.1% ± 1.1% (mean ± SE), 11.3% ± 0.9% for those
taking pramlintide plus phentermine, 3.7% ± 0.7% with
pramlintide alone, and 2.2%±0.7% with placebo (P<. 001)
[85]. Common side eﬀects experienced with combination
treatments were nausea and increased heart rate [85]. There
was a signiﬁcant increase in heart rate and blood pressure
with the combination of pramlintide and sibutramine (3.1±
1.2 beats/min, P<. 05; 2.7 ± 0.9mmHg, P<. 01) and
pramlintide with phentermine (4.5 ± 1.3 beats/min, P<
.01; 3.5 ± 1.2mmHg,P<. 001). Pramlintide is also being
investigated with exenatide, the GLP-1 agonist used for the
treatment of obesity in diabetic and non-diabetic patients
[113].
5. Conclusion
Pharmacological interventions in addition to lifestyle
changes (diet and physical activity) and in some cases
behavioural modiﬁcations are used to promote weight loss.
At present, only two drugs are currently approved and
available for the long-term treatment of obesity—orlistat
and sibutramine. However, there are several drugs and
combination drug therapies undergoing Phase III trials that
may be approved in the next few years. Pharmacotherapies
have demonstrated a signiﬁcant though modest decrease in
weight compared to placebo over 1-2 years. Unfortunately
weight loss following pharmacological intervention is not
sustained when therapy is discontinued with individuals
regaining some or all of the weight that was originally lost.
Obesity is often considered a chronic disease, hence
it requires long-term therapy. Currently, there is a lack
of high quality evidence from long-term studies of both
the eﬃcacy and safety of pharmacological interventions
for obesity. Serious safety concerns have resulted in the
withdrawalofsomedrugsthathadoriginallyreceivedmarket
approval whilst other drugs have been abandoned during
Phase III evaluation. An increase in psychiatric disorders fol-
lowing Phase III studies (RIO-Europe, RIO-North America,
RIO-Diabetes and RIO-Lipids) with rimonabant treatment
resulted in its withdrawal from the European market twoJournal of Obesity 13
years after its approval. Orlistat treatment is associated
w i t ht r o u b l e s o m es i d ee ﬀects such as diarrhoea, ﬂatulence,
bloating, abdominal pain, and dyspepsia which may not be
acceptable to some patients on long-term treatment whilst
the recent concerns of severe liver disease have led to a
review of its safety. Long-term treatment with sibutramine
is associated with a positive though modest eﬃcacy proﬁle
and a low risk proﬁle for neuropsychiatric adverse events;
however we will need to wait for the publication of the
full results of the SCOUT study to determine if there is an
increase rate of CV events in patients with cardiovascular
disease and diabetes.
Among the drugs in late phase trials, lorcaserin appears
tobeapotentialcandidateforlong-termtreatmentinobesity
due to its demonstrated eﬃcacy and tolerable safety proﬁle.
Treatment with topiramate and taranabant result in signiﬁ-
cant weight loss in long-term studies, however both of these
drugs have serious adverse eﬀects. In the case of taranabant
the psychiatric adverse events have led to the discontinuation
of Phase III trials. Amongst the combination therapies both
bupropion with naltrexone and bupropion with zonisamide
have demonstrated eﬀective weight loss and appear to be
generallywelltoleratedbasedonpublishedresultsfromRCTs
whereas there appears to be concerns regarding the safety of
combination therapy using topiramate with phentermine.
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